Cargando…
Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
The treatment paradigm for hepatocellular carcinoma (HCC) had been stagnant until recently, with new combinations of targeted and immunotherapies entering the first- and second-line setting for patients with advanced disease. This improvement in therapeutic options is well timed given the rise in ra...
Autores principales: | Marron, Thomas U, Schwartz, Myron, Corbett, Virginia, Merad, Miriam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252295/ https://www.ncbi.nlm.nih.gov/pubmed/35794901 http://dx.doi.org/10.2147/JHC.S340935 |
Ejemplares similares
-
Single-cell profiling to transform immunotherapy usage and target discovery in immune-mediated inflammatory diseases
por: Chapelle, Nicolas, et al.
Publicado: (2022) -
Neoadjuvant Therapy for Hepatocellular Carcinoma
por: Yin, Zongyi, et al.
Publicado: (2022) -
Neoadjuvant treatment strategies for hepatocellular carcinoma
por: Xu, Lei, et al.
Publicado: (2021) -
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
por: Akateh, Clifford, et al.
Publicado: (2019) -
Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)